FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147579220> ?p ?o ?g. }

• W2147579220 endingPage "151" @default.
• W2147579220 startingPage "151" @default.
• W2147579220 abstract "To evaluate the acute toxicity of rofecoxib during concurrent use with cisplatin-based chemoradiotherapy (CCRT) in patients with cervical cancer.We evaluated 67 FIGO stage IB2-IVA cervical cancer patients treated with CCRT between June 2002 and July 2004. The study group included patients who received rofecoxib (N=30) and the control group included patients who received CCRT only (N=37). The patients' medical records were retrospectively reviewed for patient characteristics, toxicity related to CCRT and treatment results.There were no significant differences in toxicity between the two groups. The most common acute grade 3/4 toxicity was neutropenia (13.3% in the study group and 21.6% in the control group). Grade 3/4 late toxicity was observed in 2 (6.6%) patients in the study group and 3 (8.1%) in the control group. There was no treatment-related deaths in either group. Six (20.0%) patients in the study group had treatment failure. In the control group, 6 (16.2%) patients experienced treatment failure. Progression-free and overall survival was 55.8+/-4.2 and 59.0+/-2.8 months, respectively, in the study group, and 69.7+/-4.3 and 71.6+/-3.6 months, respectively, in the control group. There were no differences in progression-free and overall survival between the 2 groups.Our data indicate that rofecoxib, at a dose of 25 mg twice daily, has acceptable acute toxicity as a radiosensitizer during CCRT. Although rofecoxib was not efficacious as a radiosensitizer in the present study, the benefit of rofecoxib as a radiosensitizer should be further evaluated in a prospective study." @default.
• W2147579220 created "2016-06-24" @default.
• W2147579220 creator A5010364211 @default.
• W2147579220 creator A5011820684 @default.
• W2147579220 creator A5014854865 @default.
• W2147579220 creator A5027873499 @default.
• W2147579220 creator A5039595887 @default.
• W2147579220 creator A5042172035 @default.
• W2147579220 creator A5060262766 @default.
• W2147579220 creator A5075247114 @default.
• W2147579220 date "2009-01-01" @default.
• W2147579220 modified "2023-10-02" @default.
• W2147579220 title "Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cancer" @default.
• W2147579220 cites W104147802 @default.
• W2147579220 cites W1935824237 @default.
• W2147579220 cites W1948899050 @default.
• W2147579220 cites W1970895498 @default.
• W2147579220 cites W1971334952 @default.
• W2147579220 cites W1974556177 @default.
• W2147579220 cites W1995624564 @default.
• W2147579220 cites W1999118653 @default.
• W2147579220 cites W2002354023 @default.
• W2147579220 cites W2010693411 @default.
• W2147579220 cites W2059564390 @default.
• W2147579220 cites W2107402652 @default.
• W2147579220 cites W2110844151 @default.
• W2147579220 cites W2118863945 @default.
• W2147579220 cites W2157719711 @default.
• W2147579220 cites W2164479830 @default.
• W2147579220 cites W2167503494 @default.
• W2147579220 cites W2314753133 @default.
• W2147579220 cites W2324392028 @default.
• W2147579220 cites W2328935341 @default.
• W2147579220 cites W2336169581 @default.
• W2147579220 doi "https://doi.org/10.3802/jgo.2009.20.3.151" @default.
• W2147579220 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2757559" @default.
• W2147579220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19809548" @default.
• W2147579220 hasPublicationYear "2009" @default.
• W2147579220 type Work @default.
• W2147579220 sameAs 2147579220 @default.
• W2147579220 citedByCount "2" @default.
• W2147579220 countsByYear W21475792202012 @default.
• W2147579220 countsByYear W21475792202019 @default.
• W2147579220 crossrefType "journal-article" @default.
• W2147579220 hasAuthorship W2147579220A5010364211 @default.
• W2147579220 hasAuthorship W2147579220A5011820684 @default.
• W2147579220 hasAuthorship W2147579220A5014854865 @default.
• W2147579220 hasAuthorship W2147579220A5027873499 @default.
• W2147579220 hasAuthorship W2147579220A5039595887 @default.
• W2147579220 hasAuthorship W2147579220A5042172035 @default.
• W2147579220 hasAuthorship W2147579220A5060262766 @default.
• W2147579220 hasAuthorship W2147579220A5075247114 @default.
• W2147579220 hasBestOaLocation W21475792202 @default.
• W2147579220 hasConcept C121608353 @default.
• W2147579220 hasConcept C126322002 @default.
• W2147579220 hasConcept C141071460 @default.
• W2147579220 hasConcept C143998085 @default.
• W2147579220 hasConcept C181199279 @default.
• W2147579220 hasConcept C185592680 @default.
• W2147579220 hasConcept C2776428644 @default.
• W2147579220 hasConcept C2777063308 @default.
• W2147579220 hasConcept C2778220009 @default.
• W2147579220 hasConcept C2778582115 @default.
• W2147579220 hasConcept C2779689624 @default.
• W2147579220 hasConcept C29730261 @default.
• W2147579220 hasConcept C509974204 @default.
• W2147579220 hasConcept C55493867 @default.
• W2147579220 hasConcept C71924100 @default.
• W2147579220 hasConcept C90924648 @default.
• W2147579220 hasConceptScore W2147579220C121608353 @default.
• W2147579220 hasConceptScore W2147579220C126322002 @default.
• W2147579220 hasConceptScore W2147579220C141071460 @default.
• W2147579220 hasConceptScore W2147579220C143998085 @default.
• W2147579220 hasConceptScore W2147579220C181199279 @default.
• W2147579220 hasConceptScore W2147579220C185592680 @default.
• W2147579220 hasConceptScore W2147579220C2776428644 @default.
• W2147579220 hasConceptScore W2147579220C2777063308 @default.
• W2147579220 hasConceptScore W2147579220C2778220009 @default.
• W2147579220 hasConceptScore W2147579220C2778582115 @default.
• W2147579220 hasConceptScore W2147579220C2779689624 @default.
• W2147579220 hasConceptScore W2147579220C29730261 @default.
• W2147579220 hasConceptScore W2147579220C509974204 @default.
• W2147579220 hasConceptScore W2147579220C55493867 @default.
• W2147579220 hasConceptScore W2147579220C71924100 @default.
• W2147579220 hasConceptScore W2147579220C90924648 @default.
• W2147579220 hasIssue "3" @default.
• W2147579220 hasLocation W21475792201 @default.
• W2147579220 hasLocation W21475792202 @default.
• W2147579220 hasLocation W21475792203 @default.
• W2147579220 hasLocation W21475792204 @default.
• W2147579220 hasOpenAccess W2147579220 @default.
• W2147579220 hasPrimaryLocation W21475792201 @default.
• W2147579220 hasRelatedWork W1999089432 @default.
• W2147579220 hasRelatedWork W2070138482 @default.
• W2147579220 hasRelatedWork W2168923614 @default.
• W2147579220 hasRelatedWork W2384708512 @default.
• W2147579220 hasRelatedWork W2891579355 @default.
• W2147579220 hasRelatedWork W3005553309 @default.

• next